Entresto (sacubitril/valsartan): new heart failure combination tablet 'could replace ACE inhibitors as mainstay of treatment'

A combination of valsartan and the new drug sacubitril is the first treatment to show a significant mortality benefit over enalapril in patients with heart failure. The combined tablet, Entresto, is now available to prescribe.

by Moriam Adetokunboh-Ajala
Sacubitril is combined with valsartan to provide the additional benefit of RAS blockade. | SCIENCE PHOTO LIBRARY
Sacubitril is combined with valsartan to provide the additional benefit of RAS blockade. | SCIENCE PHOTO LIBRARY

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package